The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
April 18th 2025
Real-world data support momelotinib as an effective and well-tolerated treatment for myelofibrosis-related anemia.
Study: Ripretinib BID Well-Tolerated With Similar Safety Profile to Ripretinib QD in GIST
June 23rd 2021Primary results from the randomized portion of the INVICTUS study had previously shown that ripretinib was able to significantly improve progression-free survival with a clinically meaningful overall survival benefit in patients with advanced gastrointestinal stromal tumor.
Read More
BET Inhibitors May Be Effective In Preventing Certain Types of Prostate Cancer Drug Resistance
June 21st 2021According to the study, lineage plasticity—the shift in castration-resistant prostate cancers from resembling glandular cells to neuroendocrine cells—may potentially be overcome through the use of bromodomain and extra-terminal (BET) protein inhibitors.
Read More
Study Finds No Benefit to Adding Checkpoint Inhibitors to Anti-HER2 Breast Cancer Therapy
June 21st 2021The trial, in phase 3, is the first to report data comparing a neoadjuvant anti-HER2 based regimen with or without the anti-PD-L1 antibody, atezolimumab, in patients with high-risk, HER2-positive early breast cancer.
Read More
Pharmacist Medication Insights: Tepotinib for Non-Small Cell Lung Cancer
June 21st 2021Earlier this year, the FDA granted accelerated approval to tepotinib (Tepmetko, EMD Serono Inc) for the treatment of adults with metastatic non-small cell lung cancer who are harboring MET exon 14 skipping alterations.
Watch
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
June 16th 2021Avapritinib is approved for adult patients with advanced systemic mastocytosis, including individuals with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia.
Read More
Daratumumab Demonstrates Benefit to Overall Survival for Certain Patients with Multiple Myeloma
June 16th 2021The addition of daratumumab to lenalidomide and dexamethasone resulted in a significant benefit to overall survival in patients with newly diagnosed multiple myeloma who were ineligible for autologous stem cell transplant and were treated to progression, according to the results of the phase 3 MAIA study.
Read More
The Multiple Myeloma Treatment Pipeline and Specialty Pharmacy
June 15th 2021Dealing with a cancer diagnosis is difficult, but patients with MM have reason to be hopeful. Survival rates are on the rise, and a robust pipeline of promising immunotherapies and novel treatment options are in development.
Read More